Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT04483778Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Jul 2020
- Primary completion
- Dec 2040
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCB-276 in solid tumor, germ cell tumor (GCT), retinoblastoma (Rb) and 14 more (3 arms), sponsored by Seattle Children's. Primary endpoints: Safety and tolerability of cellular immunotherapy at 28 days, Maximum Tolerated Dose at 28 days and 3 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
BCB-276
03
Conditions
solid tumorgerm cell tumor (GCT)retinoblastoma (Rb)hepatoblastomaWilms' tumor
Beyond the preview
Go deeper on NCT04483778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483778.